Germany-based biotech company Affimed Therapeutics has announced that enrollments has begun for its Phase I study of the company's anti-CD30 treatment for Hodgkins lymphoma (HL).
The treatment, called AFM13 TandAb antibody, is described by Affimed Therapeutics as such:
"AFM13 TandAb antibody is an innovative tetravalent, bispecific antibody" based on proprietary technology that "binds the CD30 target molecule on the surface of Reed-Sternberg tumor cells and simultaneously activates natural killer (NK) cells."
The company hopes to enroll at least 40 patients in this Phase I study. The drug has already received orphan drug status in both Europe and the United States.
CANCER TYPE(S)
Hodgkins lymphoma
TREATMENT TYPE(S)
Targeted anti-CD30 treatment
Source
Therapeutics Daily
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
